These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 20521348)

  • 1. Prognostic significance of mucin and p53 expression in stage IB non-small cell lung cancer: a laboratory companion study to CALGB 9633.
    Graziano SL; Gu L; Wang X; Tatum AH; Vollmer RT; Strauss GM; Kratzke R; Dudek AZ; Vokes EE; Green MR; ; ;
    J Thorac Oncol; 2010 Jun; 5(6):810-7. PubMed ID: 20521348
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cross-validation analysis of the prognostic significance of mucin expression in patients with resected non-small cell lung cancer treated with adjuvant chemotherapy: results from IALT, JBR.10 and ANITA.
    Graziano SL; Lacas B; Vollmer R; Kratzke R; Popper H; Filipits M; Seymour L; Shepherd FA; Rosell R; Veillard AS; Taron M; Pignon JP
    Lung Cancer; 2013 Oct; 82(1):149-55. PubMed ID: 23920379
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups.
    Strauss GM; Herndon JE; Maddaus MA; Johnstone DW; Johnson EA; Harpole DH; Gillenwater HH; Watson DM; Sugarbaker DJ; Schilsky RL; Vokes EE; Green MR
    J Clin Oncol; 2008 Nov; 26(31):5043-51. PubMed ID: 18809614
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
    Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
    BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The prognostic effect of single and multiple cancer-related somatic mutations in resected non-small-cell lung cancer.
    Jao K; Tomasini P; Kamel-Reid S; Korpanty GJ; Mascaux C; Sakashita S; Labbé C; Leighl NB; Liu G; Feld R; Bradbury PA; Hwang DM; Pintilie M; Tsao MS; Shepherd FA
    Lung Cancer; 2018 Sep; 123():22-29. PubMed ID: 30089591
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CYP2E1 polymorphism, cigarette smoking, p53 expression, and survival in non-small cell lung cancer: a long term follow-up study.
    Haque AK; Au W; Cajas-Salazar N; Khan S; Ginzel AW; Jones DV; Zwischenberger JB; Xie J
    Appl Immunohistochem Mol Morphol; 2004 Dec; 12(4):315-22. PubMed ID: 15536330
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical significance of Ki-67 and p53 expression in curatively resected non-small cell lung cancer.
    Ahn HK; Jung M; Ha SY; Lee JI; Park I; Kim YS; Hong J; Sym SJ; Park J; Shin DB; Lee JH; Cho EK
    Tumour Biol; 2014 Jun; 35(6):5735-40. PubMed ID: 24737581
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic value of immunohistochemical expressions of p53, HER-2/neu, and bcl-2 in stage I non-small-cell lung cancer.
    Han H; Landreneau RJ; Santucci TS; Tung MY; Macherey RS; Shackney SE; Sturgis CD; Raab SS; Silverman JF
    Hum Pathol; 2002 Jan; 33(1):105-10. PubMed ID: 11823980
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of excision repair cross-complementation group 1 protein predicts poor outcome in patients with small cell lung cancer.
    Lee HW; Han JH; Kim JH; Lee MH; Jeong SH; Kang SY; Choi JH; Oh YT; Park KJ; Hwang SC; Sheen SS; Lim HY
    Lung Cancer; 2008 Jan; 59(1):95-104. PubMed ID: 17889401
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic value of the expression of p53, bcl-2, and bax oncoproteins, and neovascularization in patients with radically resected non-small-cell lung cancer.
    Apolinario RM; van der Valk P; de Jong JS; Deville W; van Ark-Otte J; Dingemans AM; van Mourik JC; Postmus PE; Pinedo HM; Giaccone G
    J Clin Oncol; 1997 Jun; 15(6):2456-66. PubMed ID: 9196162
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictive survival markers in patients with surgically resected non-small cell lung carcinoma.
    Moldvay J; Scheid P; Wild P; Nabil K; Siat J; Borrelly J; Marie B; Farré G; Labib T; Pottier G; Sesboüé R; Bronner C; Vignaud JM; Martinet Y; Martinet N
    Clin Cancer Res; 2000 Mar; 6(3):1125-34. PubMed ID: 10741743
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic and predictive importance of p53 and RAS for adjuvant chemotherapy in non small-cell lung cancer.
    Tsao MS; Aviel-Ronen S; Ding K; Lau D; Liu N; Sakurada A; Whitehead M; Zhu CQ; Livingston R; Johnson DH; Rigas J; Seymour L; Winton T; Shepherd FA
    J Clin Oncol; 2007 Nov; 25(33):5240-7. PubMed ID: 18024870
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The prognostic significance of p53 and bcl-2 expression in lung adenocarcinoma and its correlation with Ki-67 growth fraction.
    Ishida H; Irie K; Itoh T; Furukawa T; Tokunaga O
    Cancer; 1997 Sep; 80(6):1034-45. PubMed ID: 9305703
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationship of p53 overexpression and up-regulation of proliferating cell nuclear antigen with the clinical course of non-small cell lung cancer.
    Ebina M; Steinberg SM; Mulshine JL; Linnoila RI
    Cancer Res; 1994 May; 54(9):2496-503. PubMed ID: 7909277
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic significance of bcl-2 expression in resected pN2 non-small cell lung cancer.
    Tomita M; Matsuzaki Y; Edagawa M; Shimizu T; Hara M; Onitsuka T
    Eur J Surg Oncol; 2003 Oct; 29(8):654-7. PubMed ID: 14511612
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic significance of ERCC1, RRM1 and BRCA1 in surgically-treated patients with non-small cell lung cancer.
    Pesta M; Kulda V; Fiala O; Safranek J; Topolcan O; Krakorova G; Cerny R; Pesek M
    Anticancer Res; 2012 Nov; 32(11):5003-10. PubMed ID: 23155271
    [TBL] [Abstract][Full Text] [Related]  

  • 17. p53 accumulation associated with bcl-2, the proliferation marker MIB-1 and survival in patients with prostate cancer subjected to watchful waiting.
    Borre M; Stausbol-Gron B; Overgaard J
    J Urol; 2000 Sep; 164(3 Pt 1):716-21. PubMed ID: 10953132
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BCL-2 expression is prognostic for improved survival in non-small cell lung cancer.
    Renouf DJ; Wood-Baker R; Ionescu DN; Leung S; Masoudi H; Gilks CB; Laskin J
    J Thorac Oncol; 2009 Apr; 4(4):486-91. PubMed ID: 19240654
    [TBL] [Abstract][Full Text] [Related]  

  • 19. bcl-2 and p53 protein expression in non-small cell lung cancers: correlation with survival time.
    Ohsaki Y; Toyoshima E; Fujiuchi S; Matsui H; Hirata S; Miyokawa N; Kubo Y; Kikuchi K
    Clin Cancer Res; 1996 May; 2(5):915-20. PubMed ID: 9816250
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic significance of K-ras, p53, bcl-2, PCNA, CD34 in radically resected non-small cell lung cancers.
    Grossi F; Loprevite M; Chiaramondia M; Ceppa P; Pera C; Ratto GB; Serrano J; Ferrara GB; Costa R; Boni L; Ardizzoni A
    Eur J Cancer; 2003 Jun; 39(9):1242-50. PubMed ID: 12763212
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.